英文药名: IMUSERA Capsules（Fingolimod Hydrochloride）
IMUSERA Capsules 0.5mg
在复发 - 缓解EAE小鼠，多发性硬化症，当芬戈莫德治疗口服给药表现出神经系统症状复发抑制作用的动物模型。
IMUSERA Capsules（Fingolimod hydrochloride）
IMUSERA Capsules 0.5mg（イムセラカプセル0.5mg）
Brand name : IMUSERA Capsules 0.5mg
Active ingredient: Fingolimod hydrochloride
Dosage form: bright yellow/white capsule, major axis: 15.9 mm, minor axis: 5.8 mm
Print on wrapping: イムセラ 0.5mg, IMUSERA0.5mg
Effects of this medicine
This medicine acts on lymphocytes, inhibiting lymphocytes egress, including the autoreactive T-cells that attack the patient's own nervous system, from lymph nodes and other secondary lymphoid tissue, thus reduces nerve inflammation.
It is usually used to prevent recurrence of multiple sclerosis, and to suppress progression of physical disability due to this disease.
Before using this medicine, be sure to tell your doctor and pharmacist
•If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
If you have: infections, second-degree or greater atrioventricular block, sick sinus syndrome, ischemic heart disease, congestive heart failure, low heart rate, macular oedema, diabetes mellitus, history of uveitis, hepatic dysfunction or its history, no history of varicella or herpes zoster who have not been vaccinated.
•If you are pregnant, possibly pregnant or breastfeeding.
•If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)
Dosing schedule (How to take this medicine)
•Your dosing schedule prescribed by your doctor is <<to be written by a healthcare professional>>
•In general, for adults, take 1 capsule (0.5 mg of fingolimod) at a time, once a day. Strictly follow the instructions.
•Electrocardiography should be carried out before and 6 hours after the initial dose. In addition, the measurement of heart rate and blood pressure, and continuous electrocardiographic monitoring may be carried out for 24 hours after the initial dose. If you notice symptoms of bradyarrhythmia such as dizziness, fatigue or palpitations, consult with your doctor immediately.
•If you missed a dose, take a dose as soon as possible. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. You should never take two doses at one time.
•If you accidentally take more than your prescribed dose, consult with your doctor or pharmacist.
•Do not stop taking this medicine unless your doctor instructs you to do so. If you restart this medicine after stop taking it, consult with your doctor.
Precautions while taking this medicine
•Serious infections may occur after taking this medicine. If you notice symptoms of infection, such as fever or malaise, contact with your doctor immediately. The effects of this medicine continue for up to 2 months after you stop taking it, so you should be aware of the possibility of developing infectious disease during that time.
•The medicine may cause dizziness and light-headedness in the beginning of the treatment. Take care in driving a car or operating machinery requiring alertness.
•Do not receive live vaccines during the treatment because infection may occur by the vaccines. Consult with your doctor or pharmacist when you receive vaccines.
•You should avoid getting pregnant while taking this medicine, and for up to 2 months after you stop taking it.
Possible adverse reactions to this medicine
The most commonly reported adverse reactions include nasopharyngitis, bradycardia and headache. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
•malaise, fever [infection]
•dizziness, fatigue, palpitation [bradyarrhythmia (bradycardia, atrioventricular block, etc.)]
•blurred vision, decreased visual acuity [macular oedema]
•generalized lymph node enlargement, fever, decreased weight [malignant lymphoma]
•disturbed consciousness, convulsion, visual disturbance [posterior reversible encephalopathy]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.
Storage conditions and other information
•Keep out of the reach of children. Store at 25℃ or lower and away from direct sunlight, heat, moisture and freezing.
•Discard the remainder. Do not store them. Consult with your dispensing pharmacy or healthcare provider when you discard the remainder.
Mitsubishi Tanabe Pharma CorporationInternal
The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.